# OnCo record paper-cepheus-dara-vrd-natmed-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-cepheus-dara-vrd-natmed-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-cepheus-dara-vrd-natmed-2025" ;
  schema:name "CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint"@en ;
  schema:description "In patients who were transplant-ineligible or deferred transplant, the daratumumab quadruplet raised deep-remission rates from about 39% to 61% and cut progression risk by 43%."@en ;
  schema:url <https://onco.cc/key-papers/paper-cepheus-dara-vrd-natmed-2025/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=CEPHEUS%20daratumumab%20bortezomib%20lenalidomide%20transplant-ineligible%20Usmani%20Nature%20Medicine%202025>, <https://clinicaltrials.gov/study/NCT03652064> ;
  schema:sameAs <https://doi.org/10.1038/s41591-024-03485-7> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Usmani SZ, Facon T, Hungria V, et al." ;
  onco:related <https://onco.cc/key-papers/paper-maia-daratumumab-rd-nejm-2019/> ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/> ;
  onco:targets <https://onco.cc/targets/cd38/> ;
  onco:drugs <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/lenalidomide/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:terms <https://onco.cc/terms/mrd-negativity-myeloma/>, <https://onco.cc/terms/pfs/> ;
  onco:trials <https://onco.cc/trials/cepheus/>, <https://onco.cc/trials/imroz/> ;
  onco:people <https://onco.cc/people/saad-usmani/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-dormancy-mrd/> ;
  onco:journals <https://onco.cc/journals/nature-medicine/> .